Boston Trust Walden Corp cut its holdings in InMode Ltd. (NASDAQ:INMD - Free Report) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,408,071 shares of the healthcare company's stock after selling 34,962 shares during the period. Boston Trust Walden Corp owned about 1.68% of InMode worth $23,867,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also modified their holdings of the company. Allspring Global Investments Holdings LLC lifted its position in InMode by 9.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 7,645 shares of the healthcare company's stock valued at $165,000 after purchasing an additional 691 shares during the last quarter. Hohimer Wealth Management LLC lifted its position in InMode by 6.5% in the 1st quarter. Hohimer Wealth Management LLC now owns 14,923 shares of the healthcare company's stock valued at $322,000 after purchasing an additional 906 shares during the last quarter. Headlands Technologies LLC lifted its position in InMode by 118.2% in the 1st quarter. Headlands Technologies LLC now owns 1,916 shares of the healthcare company's stock valued at $41,000 after purchasing an additional 1,038 shares during the last quarter. ProShare Advisors LLC lifted its position in InMode by 8.5% in the 1st quarter. ProShare Advisors LLC now owns 13,920 shares of the healthcare company's stock valued at $301,000 after purchasing an additional 1,094 shares during the last quarter. Finally, Cetera Advisors LLC lifted its position in InMode by 8.9% in the 1st quarter. Cetera Advisors LLC now owns 17,028 shares of the healthcare company's stock valued at $368,000 after purchasing an additional 1,394 shares during the last quarter. 68.04% of the stock is owned by institutional investors and hedge funds.
InMode Price Performance
INMD traded down $0.15 on Friday, reaching $17.55. 745,360 shares of the company traded hands, compared to its average volume of 1,316,125. The stock's 50 day moving average price is $16.48 and its 200-day moving average price is $17.36. InMode Ltd. has a 52-week low of $14.87 and a 52-week high of $26.80. The company has a market cap of $1.47 billion, a price-to-earnings ratio of 8.32 and a beta of 2.17.
InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The healthcare company reported $0.34 EPS for the quarter, missing analysts' consensus estimates of $0.38 by ($0.04). The company had revenue of $102.60 million for the quarter, compared to analysts' expectations of $104.81 million. InMode had a net margin of 35.81% and a return on equity of 21.00%. The business's revenue for the quarter was down 24.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.65 earnings per share. As a group, equities research analysts forecast that InMode Ltd. will post 1.58 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts have commented on the stock. BTIG Research assumed coverage on shares of InMode in a research report on Thursday, October 17th. They set a "buy" rating and a $25.00 price target on the stock. Barclays dropped their price target on shares of InMode from $29.00 to $27.00 and set an "overweight" rating on the stock in a research report on Monday, October 14th. Jefferies Financial Group downgraded shares of InMode from a "buy" rating to a "hold" rating and dropped their price target for the stock from $21.00 to $19.00 in a research report on Tuesday, July 23rd. Canaccord Genuity Group lowered their price objective on shares of InMode from $21.00 to $16.00 and set a "hold" rating on the stock in a research note on Friday, July 12th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research note on Thursday, October 10th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $22.60.
Get Our Latest Report on InMode
About InMode
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Further Reading
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
